Regulus Therapeutics (NASDAQ:RGLS) Cut to “Hold” at Zacks Investment Research

Regulus Therapeutics (NASDAQ:RGLS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Thursday, Zacks.com reports.

According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “

Other equities research analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating on shares of Regulus Therapeutics in a research report on Wednesday, August 11th. Cantor Fitzgerald assumed coverage on shares of Regulus Therapeutics in a report on Thursday, September 2nd. They issued an “overweight” rating and a $2.00 target price on the stock.

Regulus Therapeutics stock opened at $0.53 on Thursday. Regulus Therapeutics has a 52 week low of $0.45 and a 52 week high of $2.32. The firm’s 50-day simple moving average is $0.72 and its 200 day simple moving average is $0.92. The firm has a market capitalization of $46.36 million, a PE ratio of -2.32 and a beta of 2.22.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings data on Tuesday, August 10th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). As a group, research analysts forecast that Regulus Therapeutics will post -0.3 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in RGLS. Acadian Asset Management LLC purchased a new position in Regulus Therapeutics in the 1st quarter valued at about $726,000. Geode Capital Management LLC lifted its holdings in shares of Regulus Therapeutics by 493.5% during the 1st quarter. Geode Capital Management LLC now owns 381,892 shares of the biopharmaceutical company’s stock worth $595,000 after acquiring an additional 317,545 shares during the period. Northern Trust Corp lifted its holdings in shares of Regulus Therapeutics by 198.4% during the 1st quarter. Northern Trust Corp now owns 117,654 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 78,223 shares during the period. Atom Investors LP purchased a new position in shares of Regulus Therapeutics during the 1st quarter worth about $526,000. Finally, Ikarian Capital LLC purchased a new position in shares of Regulus Therapeutics during the 1st quarter worth about $1,943,000. Institutional investors own 26.41% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Featured Story: Understanding Average Daily Trade Volume

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.